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lymph nodes are not routinely sampled or harvested,
understaging can occur.1
A technique for intraoperative mapping of the pattern
of regional lymph node drainage for patients with a
variety of solid tumors has been developed. Original
investigators infiltrated peritumoral tissues with a
lipophilic vital dye that spreads rapidly into the lym-
phatic channels. Experience with melanoma2 and breast
cancer3 demonstrated that selective dissection of the
lymph node that stained first was accurate with respect
to prediction of the statuses of more distant lymph node
stations. This early-staining node has been referred to as
the sentinel lymph node. Our group used this sentinel
node lymphatic mapping technique in a group of
patients undergoing lung resection for NSCLC to deter-
mine its accuracy and usefulness in these patients.
Patients and methods
Our study was carried out in a group of 36 patients with
NSCLC, 23 men and 13 women with an age range of 48 to 74
years and a mean age of 60.1 years. The final histologic clas-
sifications were squamous cell carcinoma in 13 patients, ade-
nocarcinoma in 19 patients, and other histologic type in 4
T he prognosis of the patient with non–small cell lungcancer (NSCLC) is closely related to the pathologic
stage of the disease, with the pattern of regional lymph
node involvement a major determinant. Accurate stag-
ing information is therefore essential in developing
therapeutic strategies. These data also provide patients
with a realistic appraisal of prognosis so that they can
plan for the future. Nonetheless, consensus is lacking in
the thoracic surgical community with respect to the
benefits associated with performing regional lym-
phadenectomy during lung resection. When mediastinal
Background: The purpose of the study was to determine the accuracy and
role of the sentinel node technique in patients with non–small cell lung
cancer. Methods: This study was carried out on 36 consecutive patients
undergoing lung resection. Peritumoral tissue was infiltrated with iso-
sulfan blue dye and the first lymph node to stain was identified as a sen-
tinel node. Sensitivity and specificity of the sentinel node in predicting
the status of other lymph node stations were determined. Results:
Seventeen patients had sentinel lymph nodes. In 9 of these 17 cases nei-
ther the sentinel node nor any other lymph node contained metastatic
carcinoma. In 5 cases the sentinel node was in the mediastinum and doc-
umented unexpected N2 disease. In 19 patients no sentinel node was
found. Final lymph node statuses were N0 in 13 patients, N1 in 5, and
N2 in 1. Conclusions: The use of isosulfan blue for intraoperative lym-
phatic mapping is feasible. The specificity in our experience was good; 9
of 9 patients with negative sentinel nodes were found to be N0 on the
final pathology report. Unexpected N2 disease was found in 5 patients.
The accumulation of further experience will determine the role of the
sentinel node technique in patients with non–small cell lung cancer.
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patients. In addition to history and physical examination, all
patients were evaluated before the operation by computed
tomographic scanning of the chest and the upper abdomen to
include the liver and the adrenal glands. No metastatic dis-
ease was found. Seven of these patients underwent cervical
mediastinoscopy for paratracheal mediastinal lymph nodes
with a diameter between 1.0 and 1.5 cm. No biopsy speci-
mens revealed the presence of metastatic NSCLC. Five of the
7 were pathologically N0 and 2 had a pathologic N1 status.
Results of final preoperative clinical staging were stage I in
29 patients and stage II in 7 patients.
The intraoperative techniques were similar for all
patients. All operations were performed through a lateral
thoracotomy, with or without a muscle-sparing approach.
The incision was extended posteriorly for the 5 patients with
involvement of the chest wall. In these patients a 3-rib seg-
ment of chest wall was resected in continuity with the lung
and the primary tumor. The lung was collapsed as contralat-
eral ventilation was continued through a double-lumen endo-
tracheal tube. Visual and manual inspections of the lung and
the mediastinum were performed. Except for the primary
tumor, no significant abnormalities were seen in any patient.
A total of 5 ml isosulfan blue dye was injected in divided
doses into each quadrant of lung tissue immediately sur-
rounding the tumor. The pleura was then circumferentially
incised around the lung hilum and routine lung resection
was carried out. Ultimately, lobectomy or bilobectomy was
performed in 28 patients and pneumonectomy was per-
formed in 8. At the completion of the lung resection, para-
tracheal (American Thoracic Society [ATS] level 4), subaor-
tic (ATS level 5), subcarinal (ATS level 7), and inferior
pulmonary ligament (ATS level 9) lymph node groups were
all resected en bloc. During performance of the lung resec-
tion the first lymph node to stain blue, if any, was consid-
ered the sentinel lymph node and sent separately for perma-
nent histologic examination.
This study was approved by the Institutional Review Board
of University Medical Center of Southern Nevada. Informed
consent was obtained from the patients.
Results
Postoperative pathologic staging was as follows: (1)
Twenty-one patients (58.3%) had stage I disease, T1
N0 M0 in 11 (30.6%) and T2 N0 M0 in 10 (27.8%). (2)
Seven patients (19.4%) had stage II disease, T1 or T2
N1 M0 in 6 (16.7%) and T3 N0 M0 in 1 (2.8%). (3)
Eight patients (22.2%) had stage IIIA disease, T2 N2
M0 in 4 (11.1%), T3 N2 M0 in 2 (5.5%), and T3 N1
M0 in 2 (5.5%).
A sentinel lymph node was found in 17 of the
patients (47%). An example of the typical appearance
of a sentinel node is shown in Fig 1. In 9 of these 17
cases neither the sentinel lymph node nor any other
lymph node contained metastatic NSCLC, so nodal
staging was N0. The sentinel nodes in the other 8
patients were positive for tumor. In 3 patients the sen-
tinel or blue lymph node was either intraparenchymal
or interlobar and contained metastatic tumor (N1 dis-
ease) but all mediastinal nodes were negative. Two of
these 3 patients had a negative mediastinoscopic result.
In 5 of the 17 patients the sentinel node was in the
Fig 1. Photograph of resected right upper lobe. Parenchymal blue dye is visible, as well as a blue-stained lymph
node to the left of the bronchial stump. This sentinel node was tumor negative, as were all other lymph nodes in
this patient.
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mediastinum, paratracheal in 3 and subcarinal in 2, and
its examination documented unexpected N2 disease.
No other lymph nodes containing metastases were
found in any of these 5 patients.
In 19 of the patients (53%) no sentinel node was
found despite a careful intraoperative search. Diffuse
staining of the lung was observed, but no blue staining
of mediastinal tissues was seen. Among these 19
patients, final lymph node pathologic evaluation was
N0 in 13 cases, N1 in 5 cases, and N2 in 1 case.
These results are schematically depicted in Fig 2. In
several patients mediastinal lymph nodes were sec-
tioned before submission for histologic examination
and blue staining of the central part of several nodes,
which could not be detected on the node surface, was
found.
Discussion
This initial experience with the use of isosulfan
blue—which is lipophilic and is therefore quickly and
selectively taken up by the lymphatic system—for intra-
operative lymphatic mapping is encouraging. Sentinel
lymph nodes could be found in only approximately half
of the patients, but these results are consistent with early
experiences with use of this technique in patients with
melanoma or breast cancer. Increased experience has
since resulted in detection of sentinel nodes in more
than 90% of patients on a regular basis.2,3
Two potential benefits of the sentinel node technique
have emerged from these experiences. Previous inves-
tigators demonstrated that an upward staging of disease
occurs when this selective lymphatic mapping tech-
nique is employed.4 It appears that allowing the pathol-
ogist to focus on either a single lymph node or rela-
tively few nodes aids in finding micrometastases. With
only a single node to examine, the use of specialized
techniques, including polymerase chain reaction and
immunohistochemical tests directed toward appropri-
ate antigens, may increase the ability to detect only a
few metastatic cells.5-7 The second, and more contro-
versial, benefit of this technique is its ability to predict
a pathologic N0 staging status when no metastases are
present in the sentinel node. If this hypothesis is valid,
patients are spared more extensive lymph node dissec-
tion. If it is invalid, patients lose the potential benefits
of lymphadenectomy.
In our experience the specificity was excellent. All 9
patients with tumor-negative sentinel nodes were found
to have N0 disease on final pathologic examination after
a systematic mediastinal lymphadenectomy. Interest-
ingly, of the 19 patients without a sentinel lymph node
found, 18 were either N0 or N1. Further experience will
help to determine whether this is because of diffuse
lymphatic drainage and therefore spread of the blue dye,
so that in fact there is no true sentinel lymph node in
some patients with lung cancer, or whether these results
simply reflect the learning curve inherent with this tech-
nique. The goal in the case of patients with a tumor-neg-
ative sentinel lymph node is to use this information dur-
ing the operation to guide the surgeon. If sufficient
experience documents that frozen-section determina-
tion of sentinel node tumor status is a sufficiently accu-
rate predictor of the status of mediastinal nodes, then
additional lymph node sampling or dissection would not
be necessary. We have begun obtaining frozen-section
pathologic assessment of the sentinel node, both to
determine overall accuracy and to document the relia-
bility of frozen-section analysis, because this would be
simpler than obtaining multiple frozen-section assess-
ments of several lymph nodes.8
Fig 2. Schematic depiction of results. Approximately half of the patients had a sentinel lymph node (SN) found.
The final pathologic stages (Path) of all lymph nodes are given.
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We did find unexpected N2 disease in 5 patients.
Routine harvesting of all mediastinal lymph node
groups would presumably have provided equally accu-
rate staging information, but this is not a routine aspect
of pulmonary resection operations for many, indeed
probably most, thoracic surgeons. This may be because
of the modest but real associated morbidity.1 However,
lymphadenectomy for staging, and arguably for thera-
peutic benefit, remains the gold standard for mediasti-
nal staging.
We do believe that it is likely that sensitivity of this
technique will improve in time, because surgeons
showed a learning curve with this technique in
melanoma and breast cancer.2,3 Further, accumulation
of the blue dye in the central portion of lymph nodes
implies that radioimmunologically guided techniques
could add to the sensitivity, although that approach
could also reduce the specificity by identification of a
node that does not truly represent a predominant or
exclusive lymphatic spread pattern.9 Evaluation of this
option is necessary.
Acquisition of sufficient tissue to determine the sta-
tus of both the N1 and N2 lymph node basins is an
essential responsibility of the operating thoracic sur-
geon. Although therapeutic benefit arguably may
result,10 the inarguable benefit relates to staging11 be-
cause increasingly effective multimodal therapies are
available for patients with N2 disease. With the knowl-
edge that N1 node status does not reliably predict N2
node status,12 either routine lymphadenectomy, lymph
node sampling, or the sentinel node technique should
be routinely employed.
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Discussion
Dr Douglas Wood (Seattle, Wash). Dr Morton and his col-
leagues introduced lymphatic mapping 8 years ago for
melanoma, and it has quickly demonstrated its utility, pri-
marily in such superficial malignancies as melanoma, breast,
vulvar, testicular, and thyroid cancer. Unfortunately, lym-
phatic mapping has to date made little impression on the stag-
ing of visceral malignancies, for obvious reasons of accessi-
bility of the tumor and its draining lymph nodes. Dr Little and
colleagues are to be congratulated for their straightforward
and elegant study examining the feasibility of the sentinel
lymph node technique in NSCLC. To my knowledge this is
the first presentation of lymphatic mapping for lung cancer. It
is a well-constructed pilot study of 36 patients with apparent
clinical stage I and II disease undergoing lymphatic mapping
at thoracotomy with anatomic hilar and mediastinal lymph
nodes dissections serving as each patient’s control lymphatic
staging. Some of the results are intriguing, with a 100%
specificity seen in the 9 patients with a negative sentinel
node. Other results were predictable, with 6 of 36 patients
(17%) showing occult N2 disease, which is comparable to the
published false-negative rate for chest computed tomograph-
ic staging of mediastinal lymph nodes in patients with lung
cancer. One of the results was disappointing, with fewer than
50% of patients having a sentinel lymph node discovered. I
agree with Dr Little that this low number will probably
improve significantly with experience and with the addition
of radioisotope mapping combined with the vital blue dye, as
the teams experienced with this approach in melanoma and
breast cancer have discovered. Unfortunately, however,
because of the low rate of sentinel node identification, 6 of 36
patients (17%) had N1 or N2 positive nodes that were not dis-
covered by lymphatic mapping.
Lymph node status certainly is the most important predic-
tor of prognosis in patients with NSCLC, and this study is an
important contribution that may take us another step toward
accurate preoperative staging, for which even computed
tomographic and positron emission tomographic scans have
limitations. If we could reliably find and sample sentinel
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lymph nodes before thoracotomy in patients with lung cancer,
we could potentially avoid the morbidity associated with tho-
racotomy in patients with stage IIIA or IIIB disease who
would not be expected to benefit significantly from surgical
treatment, as well as directing these patients to appropriate
clinical trials.
Dr Little, do you think that the future of this technique is
computed tomography–guided tumor injection directing
prethoracotomy lymph node sampling by mediastinoscopy,
mediastinotomy, or thoracoscopy? Do you think that it will
find a significant number of N2-positive nodes that would be
missed by routine mediastinoscopy? What were the anatomic
locations of the N2 nodes found by lymphatic mapping in
your patients? In retrospect, do you think that the lymphatic
mapping found N2-positive nodes that could not have been
discovered by mediastinoscopy before thoracotomy?
Dr Little. I appreciate your comments, and among the ben-
efits I hope for in presenting these early data to this group is
that some of you will be intrigued and will go back and use
it. That is certainly what happened with the melanoma and
breast cancer patients and how a role for lymphatic mapping
was eventually identified.
Taking your questions in reverse order, in the 5 patients with
sentinel nodes that were in the mediastinum, 1 was subaortic,
2 were paratracheal, and 2 were subcarinal. None of those
nodes would have been removed with a routine lobectomy.
Depending on one’s approach, whether simply performing
lobectomy or going to the trouble of excising those lymph node
stations, those nodes would or would not have been detected.
I think that the future is going to be interesting. I was
exposed to this technique by a coauthor, Dr Kirgan, who was
a coauthor with Dr Morton on his first paper. Not believing
that we have a consensus for the ideal approach for intraop-
erative staging, I thought that the blue node technique was
worth trying. I remain intrigued by it. Either the learning
curve has to be a real phenomenon though, and we have to be
able to detect sentinel nodes in considerably more than half
the patients, or we need to add to the sensitivity with a
radioimmunologically guided approach, which theoretically
might increase the sensitivity but decrease the specificity.
Looking at the sentinel node pathologically with more sensi-
tive techniques than just the eyeball by staining for some of
the tumor antigens that have been described in recent years
might add to the sensitivity.
Dr Wood. I agree that those lymph nodes that you men-
tioned would not have been excised with a standard lobecto-
my or pneumonectomy. My question relates to 4 of those 5
that would have been easily sampled by mediastinoscopy. I
wonder whether routine mediastinoscopy before thoracotomy
would have discovered those lymph nodes, even without the
sentinel lymph node technique.
Dr Little. I guess my position is that the key issue is that
we stage the disease in our patients well, not so much how we
stage it. It is worth pointing out, though, that results of medi-
astinoscopy were negative in 7 patients who had nodes seen
on computed tomographic scan between 1 and 1.5 cm in
diameter, and 2 of these patients had sentinel nodes that were
different lymph nodes from those sampled in the medi-
astinoscopy. I think that these techniques are all complemen-
tary. These are computed tomographic scanning, positron
emission tomographic scanning, and mediastinal node dis-
section. This is another technique that can be considered,
depending on your approach right now to lymphatic mapping
and staging. I hope that this approach can have a role in the
future, particularly if the sensitivity data hold up so that if in
fact there is a sentinel node that is tumor negative it can clearly
be shown to accurately correlate with distant lymph nodes.
Dr Wood. One technical question that we have to deal with
that the others doing sentinel lymph node mapping do not is
whether anthracosis in intrathoracic lymph nodes causes a
problem in identifying the blue node. Did you find that?
Dr Little. Yes. It seems as though everything is bluish gray.
It is a little tricky, and it may turn out that this technique is not
as good as one would like in this setting and for this patient
population. When the node is there, though, there really is no
question between blue and black; it is extremely clear.
Dr Wood. I congratulate you on this innovative and pio-
neering work. It is really intriguing, and I hope that it does give
us some progress in staging the disease in our patients better.
Dr James B. D. Mark (Stanford, Calif). Certainly this is
making good use of a technique that has been established in
other areas. I want to look ahead to see what you are going to
gain from it, however. You have made the point that systemat-
ic node dissection is really an important part of lobectomy and
pneumonectomy in lung cancer, and only in some circum-
stances do I think that this technique is going to be worth-
while. If the negative sentinel node is really as good as you
hope it is going to be but the patient has still had a thoracoto-
my, you have not saved much by preventing the node dissec-
tion. I think that the only way that this is going to be really
important is if you can somehow use this or a similar tech-
nique to determine that a patient should not have a thoracoto-
my at all, otherwise I am afraid that we have not saved much.
Dr Little. I think that if everyone practiced thoracic surgery
the way you do, that would be true, and in the setting in which
a true mediastinal lymph node harvest is going to take place
the value of this technique is limited. I suggest, however, that
most practicing thoracic surgeons do not do what you do, or
even come close to it. This technique is additive, it is comple-
mentary, it is another option. I do agree with you, however,
that the benefit of this technique is limited if you are going to
do a mediastinal node harvest in every patient.
